27 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Teva earnings preview: Israeli drugmaker to report early Wednesday https://seekingalpha.com/news/4060267-teva-earnings-preview-israeli-drugmaker-to-report-early-wednesday?source=feed_tag_israel Jan 30, 2024 - Teva Pharmaceutical Industries (TEVA) is expected to report higher Q4 earnings before market open on Wednesday, with investors looking to see if the Israeli dru
Teva to divest API unit to focus on core business strengths https://seekingalpha.com/news/4060502-teva-to-divest-api-unit-to-focus-on-core-business-strengths?source=feed_tag_israel Jan 31, 2024 - Teva plans to divest its API business as part of its growth strategy, aiming to focus on core strengths and capitalize on opportunities in the global API...
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707 Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
Teva upgraded at J.P. Morgan on upcoming catalysts https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035 Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405 Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

Pages: 123

<<<Page 3